Oligonucleotide therapeutics: 25 years agrowing

Current Opinion in Molecular Therapeutics

Volumn 6, Issue 2, 2004, Pages 120-128

  Goodchild, John ^a  

^a WORCESTER STATE UNIVERSITY   (United States)

Author keywords

Antisense oligonucleotides; Chemical modification; Hybridization; Site selection; Toxicity; Uptake

Indexed keywords

ABC TRANSPORTER; ANTISENSE OLIGONUCLEOTIDE; CHAPERONIN; DEOXYRIBOZYME; DNA; RIBONUCLEASE H; RIBONUCLEASE P; RIBOZYME; TELOMERASE;

BIOSYNTHESIS; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; REVIEW; RNA INTERFERENCE;

ATP-BINDING CASSETTE TRANSPORTERS; CHAPERONINS; DNA; DNA, CATALYTIC; OLIGONUCLEOTIDES, ANTISENSE; RIBONUCLEASE H, CALF THYMUS; RIBONUCLEASE P; RNA INTERFERENCE; RNA, CATALYTIC; TELOMERASE;

EID: 7944230575     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Stephenson ML, Zamecnik PC: Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci USA (1978) 75(1):285-288.
2. Stephenson ML, Zamecnik PC: Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA (1978) 75(1):280-284.
3. Giles RV: Antisense oligonucleotide technology: From EST to therapeutics. Curr Opin Mol Ther (2000) 2(3):238-252.
4. Dias N, Stein CA: Antisense oligonucleotides: Basic concepts and mechanisms. Mol Cancer Ther 2002 1(5):347-355.
5. Bennett CF, Cowsert LM: Application of antisense oligonucleotides for gene functionalization and target validation. Curr Opin Mol Ther (1999) 1(3):359-371.
6. Ho SP, Hartig PR: Antisense oligonucleotides for target validation in the CNS. Curr Opin Mol Ther (1999) 1(3):336-343.
7. ten Asbroek ALMA, van Groenigen M, Nooij M, Baas F: The involvement of human ribonucleases H1 and H2 in the variation of response of cells to antisense phosphorothioate oligonucleotides. Eur J Biochem (2002) 269(2):583-592.
8. Yatabe N, Kyo S, Kondo S, Kanaya T, Wang Z, Maida Y, Takakura M, Nakamura M, Tanaka M, Inoue M: 2-5A antisense therapy directed against human telomerase RNA inhibits telomerase activity and induces apoptosis without telomere impairment in cervical cancer cells. Cancer Gene Ther (2002) 9(7):624-630.
9. Leaman DW, Longano FJ, Okicki JR, Soike KF, Torrence PF, Silverman RH, Cramer H: Targeted therapy of respiratory syncytial virus in African green monkeys by intranasally administered 2-5A antisense. Virology (2002) 292(1):70-77.
10. Torrence PF: 2-5A-antisense chimeras: Inhibitors of respiratory syncytial virus infection. Curr Opin Mol Ther (1999) 1(3):307-315.
11. Kraus G, Geffin R, Spruill G, Young AK, Seivright R, Cardona D, Burzawa J, Hnatyszyn HJ: Cross-clade inhibition of HIV-1 replication and cytopathology by using RNase P-associated external guide sequences. Proc Natl Acad Sci USA (2002) 99(6):3406-3411.
12. Zhou T, Kim J, Kilani AF, Kim K, Dunn W, Jo S, Nepomuceno E, Liu F: In vitro selection of external guide sequences for directing RNase P-mediated inhibition of viral gene expression. J Biol Chem (2002) 277(33):30112-30120.
13. Dudley NR, Goldstein B: RNA interference: Silencing in the cytoplasm and nucleus. Curr Opin Mol Ther (2003) 5(2):113-117.
14. Goodchild J: Hammerhead ribozymes: Biochemical and chemical considerations. Curr Opin Mol Ther (2000) 2(3):272-281.
15. Iyo M, Kawasaki H, Taira K: Allosterically controllable maxizymes for molecular gene therapy. Curr Opin Mol Ther (2002) 4(2):154-165.
16. Khachigian LM: DNAzymes: Cutting a path to a new class of therapeutics. Curr Opin Mol Ther (2002) 4(2):119-121.
17. He QC, Zhou JM, Zhou DM, Nakamatsu Y, Baba T, Taira K: Comparison of metal-ion-dependent cleavages of RNA by a DNA enzyme and a hammerhead ribozyme. Biomacromolecules (2002) 3(1):69-83.
18. Kurreck J, Bieber B, Jahnel R, Erdmann VA: Comparative study of DNA enzymes and ribozymes against the same full-length messenger RNA of the vanilloid receptor subtype I. J Biol Chem (2002) 277(9):7099- 7107.
19. Scherer LJ, Rossi JJ: Approaches for the sequence-specific knockdown of mRNA. Nat Biotechnol (2003) 21(12):1457-1465.
20. Ørum H, Wengel J: Locked nucleic acids: A promising molecular family for gene-function analysis and antisense drug development. Curr Opin Mol Ther (2001) 3(3):239-243.
21. Renneberg D, Bouliong E, Reber U, Schumperli D, Leumann CJ: Antisense properties of tricyclo-DNA. Nucleic Acids Res (2002) 30(13):2751-2757.
22. Faria M, Spiller DG, Dubertret C, Nelson JS, White MRH, Scherman D, Helene C, Giovannangeli C: Phosphoramidate oligonucleotides as potent antisense molecules in cells and in vivo. Nat Biotechnol (2001) 19(1):40-44.
23. Nielsen PE: Antisense peptide nucleic acids. Curr Opin Mol Ther (2000) 2(3):282-287.
24. Iversen PL: Phosphorodiamidate morpholino oligomers: Favorable properties for sequence-specific gene inactivation. Curr Opin Mol Ther (2001) 3(3):235-238.
25. Kole R, Sazani P: Antisense effects in the cell nucleus: Modification of splicing. Curr Opin Mol Ther (2001) 3(3):229-234.
26. Suwanmanee T, Sierakowska H, Lacerra G, Svasti S, Kirby S, Walsh CE, Fucharoen S, Kole R: Restoration of human β-globin gene expression in murine and human IVS2-654 thalassemic erythroid cells by free uptake of antisense oligonucleotides. Mol Pharmacol (2002) 62(3):545- 553.
27. Suwanmanee T, Sierakowska H, Fucharoen S, Kole R: Repair of a splicing defect in erythroid cells from patients with β-thalassemia/HbE disorder. Mol Ther (2002) 6(6):718-726.
28. Mercatante DR, Mohler JL, Kole R: Cellular response to an antisense-mediated shift of Bcl-X pre-mRNA splicing and antineoplastic agents. J Biol Chem (2002) 277(51):49374-49382.
29. Skordis LA, Dunckley MG, Yue BG, Eperon IC, Muntoni F: Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc Natl Acad Sci USA (2003) 100(7):4114-4119.
30. Herbert BS, Pongracz K, Shay JW, Gryaznov SM, Shea-Herbert B: Oligonucleotide N3′→P5′ phosphoramidates as efficient telomerase inhibitors. Oncogene (2002) 21(4):638-642.
31. Elayadi AN, Braasch DA, Corey DR: Implications of high-affinity hybridization by locked nucleic acid oligomers for inhibition of human telomerase. Biochemistry (2002) 41(31):9973-9981.
32. Childs JL, Disney MD, Turner DH: Oligonucleotide directed misfolding of RNA inhibits Candida albicans group I intron splicing. Proc Natl Acad Sci USA (2002) 99(17):11091-11096.
33. Dirac AM, Huthoff H, Kjems J, Berkhout B: Regulated HIV-2 RNA dimerization by means of alternative RNA conformations. Nucleic Acids Res (2002) 30(12):2647-2655.
34. Hamma T, Miller PS: Interactions of hairpin oligo-2′- O-methylribonucleotides containing methylphosphonate linkages with HIV Tar RNA. Antisense Nucleic Acid Drug Dev (2003) 13(1):19-30.
35. Iyer RP, Roland A, Zhou W, Ghosh K: Modified oligonucleotides -synthesis, properties and applications. Curr Opin Mol Ther (1999) 1(3):344-358.
36. Brigui I, Djavanbakht-Samani T, Jolles B, Pigaglio S, Laigle A: Minimally modified phosphodiester antisense oligodeoxyribonucleotide directed against the multidrug resistance gene mdr1. Biochem Pharmacol (2003) 65(5):747-754.
37. Boczkowska M, Guga P, Stec WJ: Stereodefined phosphorothioate analogues of DNA: Relative thermodynamic stability of the model PS-DNA/DNA and PS-DNA/RNA complexes. Biochemistry (2002) 41(41):12483-12487.
38. Lok CN, Viazovkina E, Min KL, Nagy E, Wilds CJ, Damha MJ, Parniak MA: Potent gene-specific inhibitory properties of mixed-backbone antisense oligonucleotides comprised of 2′-deoxy-2′-fluoro-D-arabinose and 2′-deoxyribose nucleotides. Biochemistry (2002) 41(10):3457-3467.
39. Sohail M, Southern EM: Hybridization of antisense reagents to RNA. Curr Opin Mol Ther (2000) 2(3):264-271.
40. Sczakiel G, Far RK: The role of target accessibility for antisense inhibition. Curr Opin Mol Ther (2002) 4(2):149-153.
41. Bohula EA, Salisbury AJ, Sohail M, Playford MP, Riedemann J, Southern EM, Macaulay VM: The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript. J Biol Chem (2003) 278(18):15991- 15997.
42. Holen T, Amarzguioui M, Wiiger MT, Babaie E, Prydz H: Positional effects of short interfering RNAs targeting the human coagulation trigger tissue factor. Nucleic Acids Res (2002) 30(8):1757-1766.
43. Sohail M, Hochegger H, Klotzbucher A, Guellec RL, Hunt T, Southern EM: Antisense oligonucleotides selected by hybridisation to scanning arrays are effective reagents in vivo. Nucleic Acids Res (2001) 29(10):2041-2051.
44. 't Hoen PA, Out R, Commandeur JN, Vermeulen NP, van Batenburg FH, Manoharan M, van Berkel TJ, Biessen EA, Bijsterbosch MK: Selection of antisense oligodeoxynucleotides against glutathione S-transferase Mu. RNA (2002) 8(12):1572-1583.
45. Mercatanti A, Rainaldi G, Mariani L, Marangoni R, Citti L: A method for prediction of accessible sites on an mRNA sequence for target selection of hammerhead ribozymes. J Comput Biol (2002) 9(4):641-653.
46. Wrzesinski J, Legiewicz M, Ciesiolka J: Mapping of accessible sites for oligonucleotide hybridization on hepatitis δ virus ribozymes. Nucleic Acids Res (2000) 28(8):1785-1793.
47. Walton SP, Stephanopoulos GN, Yarmush ML, Roth CM: Thermodynamic and kinetic characterization of antisense oligodeoxynucleotide binding to a structured mRNA. Biophys J (2002) 82(1 Pt 1):366-377.
48. Venturini F, Braspenning J, Homann M, Gissmann L, Sczakiel G: Kinetic selection of HPV 16 E6/E7-directed antisense nucleic acids: Anti-proliferative effects on HPV 16-transformed cells. Nucleic Acids Res (1999) 27(7):1585-1592.
49. Deer EL, Douk B, Lanchy JM, Lodmell JS: Elucidation and characterization of oligonucleotide-accessible sites on HIV-2 leader region RNA. Antisense Nucleic Acid Drug Dev (2003) 13(1):45-55.
50. Futami T, Miyagishi M, Iwai S, Seki M, Taira K: Stimulatory effect of an indirectly attached RNA helicase-recruiting sequence on the suppression of gene expression by antisense oligonucleotides. Antisense Nucleic Acid Drug Dev (2003) 13(1):9-17.
51. Lebedeva I, Stein CA: Antisense oligonucleotides: Promise and reality. Annu Rev Pharmacol Toxicol (2001) 41:403-419.
52. Lai JC, Benimetskaya L, Santella RM, Wang Q, Miller PS, Stein CA: G3139 (oblimersen) may inhibit prostate cancer cell growth in a partially bis-CpG-dependent non-antisense manner. Mol Cancer Ther (2003) 2(10):1031-1043.
53. Mladinic M, Didelon F, Cherubini E, Bradbury A: 'Specific' oligonucleotides often recognize more than one gene: The limits of in situ hybridization applied to GABA receptors. J Neurosci Methods (2000) 98(1):33-42.
54. Fisher AA, Ye D, Sergueev DS, Fisher MH, Shaw BR, Juliano RL: Evaluating the specificity of antisense oligonucleotide conjugates. A DNA array analysis. J Biol Chem (2002) 277(25):22980-22984.
55. Mirmohammadsadegh A, Maschke J, Basner-Tschakarjan E, Bar A, Hengge UR: Reaction of keratinocytes to exogenous DNA. Cells Tissues Organs (2002) 172(2):86-95.
56. Juliano RL, Yoo H: Aspects of the transport and delivery of antisense oligonucleotides. Curr Opin Mol Ther (2000) 2(3):297-303.
57. Brand RM: Topical and transdermal delivery of antisense oligonucleotides. Curr Opin Mol Ther (2001) 3(3):244-248.
58. Moulton HM, Moulton JD: Peptide-assisted delivery of steric-blocking antisense oligomers. Curr Opin Mol Ther (2003) 5(2):123-132.
59. Thierry AR, Vives E, Richard J-P, Prevot P, Martinand-Mari C, Robbins I, Lebleu B: Cellular uptake and intracellular fate of antisense oligonucleotides. Curr Opin Mol Ther (2003) 5(2):133-138.
60. Wang L, Prakash RK, Stein CA, Koehn RK, Ruffner DE: Progress in the delivery of therapeutic oligonucleotides: Organ/cellular distribution and targeted delivery of oligonucleotides in vivo. Antisense Nucleic Acid Drug Dev 2003 13(3):169-189.
61. Chen Z, Monia BP, Corey DR: Telomerase inhibition, telomere shortening, and decreased cell proliferation by cell permeable 2′-O-methoxyethyl oligonucleotides. J Med Chem(2002) 45(25):5423-5425.
62. Feinberg EH, Hunter CP: Transport of dsRNA into cells by the transmembrane protein SID-1. Science (2003) 301(5639):1545- 1547.
63. Walters DK, Jelinek DF: The effectiveness of double-stranded short inhibitory RNAs (siRNAs) may depend on the method of transfection. Antisense Nucleic Acid Drug Dev (2002) 12(6):411-418.
64. Merdan T, Kunath K, Fischer D, Kopecek J, Kissel T: Intracellular processing of poly(ethylene imine)/ribozyme complexes can be observed in living cells by using confocal laser scanning microscopy and inhibitor experiments. Pharm Res (2002) 19(2):140-146.
65. Aigner A, Fischer D, Merdan T, Brus C, Kissel T, Czubayko F: Delivery of unmodified bioactive ribozymes by an RNA-stabilizing polyethylenimine (LMW-PEI) efficiently down-regulates gene expression. Gene Ther (2002) 9(24):1700-1707.
66. Kyriakides TR, Cheung CY, Murthy N, Bornstein P, Stayton PS, Hoffman AS: pH-sensitive polymers that enhance intracellular drug delivery in vivo. J Control Release (2002) 78(1-3):295-303.
67. Jensen KD, Kopeckova P, Kopecek J: Antisense oligonucleotides delivered to the lysosome escape and actively inhibit the hepatitis B virus. Bioconjug Chem (2002) 13(5):975-984.
68. Astriab-Fisher A, Sergueev D, Fisher M, Shaw BR, Juliano RL: Conjugates of antisense oligonucleotides with the Tat and antennapedia cell-penetrating peptides: Effects on cellular uptake, binding to target sequences, and biologic actions. Pharm Res (2002) 19(6):744-754.
69. Adlerz L, Soomets U, Holmlund L, Viirlaid S, Langel U, Iverfeldt K: Down-regulation of amyloid precursor protein by peptide nucleic acid oligomer in cultured rat primary neurons and astrocytes. Neurosci Lett (2003) 336(1):55-59.
70. Biessen EA, Sliedregt-Bol K, 't Hoen PA, Prince P, Van der Bilt E, Valentijn AR, Meeuwenoord NJ, Princen H, Bijsterbosch MK, Van der Marel GA, Van Boom JH, Van Berkel TJ: Design of a targeted peptide nucleic acid prodrug to inhibit hepatic human microsomal triglyceride transfer protein expression in hepatocytes. Bioconjug Chem (2002) 13(2):295-302.
71. Dvorchik BH: The disposition (ADME) of antisense oligonucleotides. Curr Opin Mol Ther (2000) 2(3):253-257.
72. Marquis JK, Grindel JM: Toxicological evaluation of oligonucleotide therapeutics. Curr Opin Mol Ther (2000) 2(3):258-263.
73. Korneev SA, Kemenes I, Straub V, Staras K, Korneeva EI, Kemenes G, Benjamin PR, O'Shea M: Suppression of nitric oxide (NO)-dependent behavior by double-stranded RNA-mediated silencing of a neuronal NO synthase gene. J Neurosci (2002) 22(11):RC227.
74. Hasuwa H, Kaseda K, Einarsdottir T, Okabe M: Small interfering RNA and gene silencing in transgenic mice and rats. FEBS Lett (2002) 532(1-2):227-230.
75. Winston WM, Molodowitch C, Hunter CP: Systemic RNAi in C. elegans requires the putative transmembrane protein SID-1. Science (2002) 295(5564):2456-2459.
76. Dzitoyeva S, Dimitrijevic N, Manev H: γ-Aminobutyric acid B receptor 1 mediates behavior-impairing actions of alcohol in Drosophila: Adult RNA interference and pharmacological evidence. Proc Natl Acad Sci USA (2003) 100(9):5485-5490.
77. Bridge AJ, Pebernard S, Ducraux A, Nicoulaz AL, Iggo R: Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet (2003) 34(3):263-264.
78. Skipper M: RNA interference: Have our dreams been shattered? Nat Rev Genet (2003) 4:671.
79. Arora V, Knapp DC, Reddy MT, Weller DD, Iversen PL: Bioavailability and efficacy of antisense morpholino oligomers targeted to c-myc and cytochrome P-450 3A2 following oral administration in rats. J Pharm Sci (2002) 91(4):1009-1018.
80. Giovannangeli C, Helene C: Triplex-forming molecules for modulation of DNA information processing. Curr Opin Mol Ther (2000) 2(3):288-296.
81. Macris MA, Glazer PM: Transcription dependence of chromosomal gene targeting by triplex-forming oligonucleotides. J Biol Chem (2003) 278(5):3357-3362.
82. Ziemba AJ, Reed MW, Raney KD, Byrd AB, Ebbinghaus SW: A bisalkylating triplex forming oligonucleotide inhibits intracellular reporter gene expression and prevents triplex unwinding due to helicase activity. Biochemistry (2003) 42(17):5013-5024.
83. Bentin T, Nielsen PE: Superior duplex DNA strand invasion by acridine conjugated peptide nucleic acids. J Am Chem Soc 2003 125(21):6378-6379.
84. Hertoghs KM, Ellis JH, Catchpole IR: Use of locked nucleic acid oligonucleotides to add functionality to plasmid DNA. Nucleic Acids Res 2003 31(2):5817-5830.
85. Stanojevic D, Young RA: A highly potent artificial transcription factor. Biochemistry (2002) 41(23):7209-7216.
86. Kandimalla ER, Yu D, Agrawal S: Towards optimal design of second-generation immunomodulatory oligonucleotides. Curr Opin Mol Ther (2002) 4(2):122-129.
87. Rothenfusser S, Tuma E, Wagner M, Endres S, Hartmann G: Recent advances in immunostimulatory CpG oligonucleotides. Curr Opin Mol Ther (2003) 5(2):98-106.
88. Cho-Chung YS, Park YG, Lee YN: Oligonucleotides as transcription factor decoys. Curr Opin Mol Ther (1999) 1(3):386-392.
89. Tomita N, Morishita R, Tomita T, Ogihara T: Potential therapeutic applications of decoy oligonucleotides. Curr Opin Mol Ther (2002) 4(2):166-170.
90. Tomita N, Tomita T, Yuyama K, Tougan T, Tajima T, Ogihara T, Morishita R: Development of novel decoy oligonucleotides: Advantages of circular dumb-bell decoy. Curr Opin Mol Ther (2003) 5(2):107-112.
91. Toulmé JJ: Aptamers: Selected oligonucleotides for therapy. Curr Opin Mol Ther (2000) 2(3):318-324.
92. Akhtar S, Dunnion D, Poyner D, Ackroyd J, Bibby M, Double J: Sequence and chemistry requirements for a novel aptameric oligonucleotide inhibitor of EGF receptor tyrosine kinase activity. Biochem Pharmacol (2002) 63(12):2187-2195.
93. Wang H, Wang S, Nan L, Yu D, Agrawal S, Zhang R: Antisense antimdm2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms. Int J Oncol (2002) 20(4):745-752.
94. Tidd DM, Broughton CM, Clark RE: CpG oligodeoxynucleotide 5mer-induced apoptosis in MOLT-4 leukaemia cells does not require caspase 3 or new protein synthesis. Nucleic Acids Res (2003) 31(9):2297-2304.
95. Hwang JT, Baltasar FE, Cole DL, Sigman DS, Chen CHB, Greenberg MM: Transcription inhibition using modified pentanucleotides. Bioorg Med Chem (2003) 11(10):2321-2328.
96. Disney MD, Haidaris CG, Turner DH: Uptake and antifungal activity of oligonucleotides in Candida albicans. Proc Natl Acad Sci USA (2003) 100(4):1530-1534.
97. Tackett AJ, Corey DR, Raney KD: Non-Watson-Crick interactions between PNA and DNA inhibit the ATPase activity of bacteriophage T4 Dda helicase. Nucleic Acids Res (2002) 30(4):950-957.